Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Apr;21(4):431–435. doi: 10.1111/j.1365-2125.1986.tb05218.x

Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.

J L Shaffer, A Kershaw, J B Houston
PMCID: PMC1400944  PMID: 2871853

Abstract

The pharmacokinetics of metronidazole were studied after oral and intravenous administration to seven patients with Crohn's disease and five patients with ulcerative colitis. The oral/intravenous availability ratio was 0.97 +/- 0.2 in the Crohn's patients and 0.90 +/- 0.1 in the colitics (mean +/- s.e. mean). Plasma clearance was 3.24 +/- 0.2 l h-1 and 4.1 +/- 0.5 l h-1, respectively. These differences were not statistically significant. Ten of the patients on long term sulphasalazine were studied to observe the effect of 2 weeks metronidazole therapy on plasma sulphapyridine concentration. The sulphapyridine concentration changed from 22.1 +/- 2.0 micrograms ml-1 to 15.95 +/- 4.5 micrograms ml-1 in the Crohn's patients and 26.0 +/- 6.0 micrograms ml-1 to 36.4 +/- 8.5 micrograms ml-1 in the colitis group, pre- and post-metronidazole. These differences were not statistically significant. These results suggest that metronidazole does not interfere with diazo-link splitting of sulphasalazine and that patients with Crohn's disease handle metronidazole in a similar manner to patients with colitis.

Full text

PDF
431

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergan T., Bjerke P. E., Fausa O. Pharmacokinetics of metronidazole in patients with enteric disease compared to normal volunteers. Chemotherapy. 1981;27(4):233–238. doi: 10.1159/000237985. [DOI] [PubMed] [Google Scholar]
  2. Broxterman H. J., van Valkenburg C. F., Noach E. L. HA-966 effects on striatal dopamine metabolism: implications for dopamine compartmentalization. J Pharm Pharmacol. 1980 Jan;32(1):67–69. doi: 10.1111/j.2042-7158.1980.tb12851.x. [DOI] [PubMed] [Google Scholar]
  3. Daneshmend T. K., Homeida M., Kaye C. M., Elamin A. A., Roberts C. J. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis. Gut. 1982 Oct;23(10):807–813. doi: 10.1136/gut.23.10.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Das K. M., Eastwood M. A., McManus J. P., Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut. 1973 Aug;14(8):631–641. doi: 10.1136/gut.14.8.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gulaid A., Houghton G. W., Lewellen O. R., Smith J., Thorne P. S. Determination of metronidazole and its two major metabolites in biological fluids by high pressure liquid chromatography. Br J Clin Pharmacol. 1978 Nov;6(5):430–432. doi: 10.1111/j.1365-2125.1978.tb04608.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Houghton G. W., Smith J., Thorne P. S., Templeton R. The pharmacokinetics of oral and intravenous metronidazole in man. J Antimicrob Chemother. 1979 Sep;5(5):621–623. doi: 10.1093/jac/5.5.621. [DOI] [PubMed] [Google Scholar]
  7. Houston J. B., Day J., Walker J. Azo reduction of sulphasalazine in healthy volunteers. Br J Clin Pharmacol. 1982 Sep;14(3):395–398. doi: 10.1111/j.1365-2125.1982.tb01997.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Krook A., Järnerot G., Danielsson D. Clinical effect of metronidazole and sulfasalazine on Crohn's disease in relation to changes in the fecal flora. Scand J Gastroenterol. 1981;16(4):569–575. doi: 10.3109/00365528109182013. [DOI] [PubMed] [Google Scholar]
  9. Melander A., Kahlmeter G., Kamme C., Ursing B. Bioavailability of metronidazole in fasting and non-fasting healthy subjects and in patients with Crohn's disease. Eur J Clin Pharmacol. 1977 Aug 17;12(1):69–72. doi: 10.1007/BF00561408. [DOI] [PubMed] [Google Scholar]
  10. Rabin H. R., Urtasun R. C., Partington J., Koziol D., Sharon M., Walker K. High-dose metronidazole: pharmacokinetics and bioavailability using an iv preparation and application of its use as a radiosensitizer. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1087–1095. [PubMed] [Google Scholar]
  11. Shaffer J. A., Williams S. E., Turnberg L. A., Houston J. B., Rowland M. Absorption of prednisolone in patients with Crohn's disease. Gut. 1983 Mar;24(3):182–186. doi: 10.1136/gut.24.3.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Shaffer J. L., Houston J. B. The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration. Br J Clin Pharmacol. 1985 Apr;19(4):526–528. doi: 10.1111/j.1365-2125.1985.tb02682.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ursing B., Alm T., Bárány F., Bergelin I., Ganrot-Norlin K., Hoevels J., Huitfeldt B., Järnerot G., Krause U., Krook A. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology. 1982 Sep;83(3):550–562. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES